We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Sample Screened for Cystic Fibrosis-Causing Mutations

By LabMedica International staff writers
Posted on 31 Aug 2010
A new diagnostic test simultaneously screens a single blood sample for up to 60 cystic fibrosis-causing genetic mutations in a matter of hours.

The comprehensive and flexible cystic fibrosis (CF) test will be used to screen potential parents to determine if they are carriers of CF-causing gene mutations, and as an aid in newborn screening and confirmatory diagnostic testing in newborns and children.

The xTAG Cystic Fibrosis 60 Kit v2 detects CFTR gene mutations including the 23 CFTR gene mutations and four variants (polymorphisms) recommended by the American College of Medical Genetics (ACMG) and American College of Obstetricians and Gynecologists (ACOG); 37 additional common North American mutations, including 20 mutations that are found within Hispanic and African-American populations are also detected

Luminex Corporation (Austin, TX, USA) introduced the xTAG Cystic Fibrosis 60 Kit v2. The test recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA; Silver Spring, MD, USA).

"The launch of our new xTAG Cystic Fibrosis 60 Kit v2 is a great achievement in cystic fibrosis testing," said Patrick J. Balthrop, president and CEO of Luminex. "This cleared test has the most comprehensive genetic mutation coverage available today, featuring mutations found among Caucasians as well as those that are more commonly found in other ethnic populations. It will give doctors the ability to screen children and potential parents of many ethnicities for CF."

CF is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. To date, more than 1,500 of these mutations have been discovered. More than 10 million Americans are symptomless carriers of CF-causing gene mutations and approximately 30,000 Americans suffer from the condition. It is a common genetic disorder that causes the body to produce thick mucus that can clog the lungs and affect the digestive system.

Luminex Corporation develops, manufactures, and markets biologic testing technologies with applications throughout the diagnostic and life sciences industries.

Related Links:
American College of Medical Genetics
American College of Obstetricians and Gynecologists
Luminex Corporation
U.S. Food and Drug Administration


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer

Latest Molecular Diagnostics News

Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
31 Aug 2010  |   Molecular Diagnostics

Urine Test Diagnoses Early-Stage Prostate Cancer
31 Aug 2010  |   Molecular Diagnostics

New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
31 Aug 2010  |   Molecular Diagnostics